These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25102859)

  • 1. Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience.
    Murias S; Alcobendas R; Pascual-Salcedo D; Remesal A; Peralta J; Merino R
    Rheumatology (Oxford); 2014 Nov; 53(11):2124-6. PubMed ID: 25102859
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
    Nolan TJ; O'Connor MB; Bond U; Swan J; Phelan MJ
    Rheumatol Int; 2013 Jul; 33(7):1907-8. PubMed ID: 22441967
    [No Abstract]   [Full Text] [Related]  

  • 5. A brief course of anti-TNF-alpha therapy can cure recurrent episodes of HLA-B27-associated severe and refractory heel enthesitis.
    Olivieri I; Giasi V; Scarano E; Gigliotti P; D'Angelo S; Padula A
    Clin Exp Rheumatol; 2009; 27(6):1057; author reply 1058. PubMed ID: 20149333
    [No Abstract]   [Full Text] [Related]  

  • 6. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
    Haraoui B
    J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
    [No Abstract]   [Full Text] [Related]  

  • 7. Methotrexate and injectable tumor necrosis factor-α inhibitor adherence and persistence in children with rheumatic diseases.
    Ringold S; Grant S; Girdish C; Wallace CA; Sullivan SD
    J Rheumatol; 2013 Jan; 40(1):80-6. PubMed ID: 23118115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha blocker induced tuberculosis.
    Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
    J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands.
    Magnano MD; Chakravarty EF; Broudy C; Chung L; Kelman A; Hillygus J; Genovese MC
    J Rheumatol; 2007 Jun; 34(6):1323-7. PubMed ID: 17516620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
    Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
    [No Abstract]   [Full Text] [Related]  

  • 13. [New strategies against autoaggressive immune system. Is rheumatism to be healable soon?].
    Meissner T
    MMW Fortschr Med; 2003 Oct; 145(42):16. PubMed ID: 14655438
    [No Abstract]   [Full Text] [Related]  

  • 14. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis.
    Hakala M; Immonen K; Korpela M; Vasala M; Kauppi MJ
    Ann Rheum Dis; 2013 Mar; 72(3):464-5. PubMed ID: 23148310
    [No Abstract]   [Full Text] [Related]  

  • 17. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of tumor necrosis factor antagonists. Proceedings of the Canadian expert roundtable meeting, Banff, Canada, November 28-30, 2003.
    J Rheumatol Suppl; 2005 Mar; 74():1-47. PubMed ID: 15742456
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab.
    Gomes KW; Benevides AN; Vieira FJ; Burlamaqui MP; Vieira Mde A; Fontenelle LM
    Rev Bras Reumatol; 2012; 52(3):447-52. PubMed ID: 22641598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Profile of use of anti tumor necrosis factor in Colombian patients].
    Machado J; Moncada JC; Pineda R
    Biomedica; 2011 Jun; 31(2):250-7. PubMed ID: 22159542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.